Home > Research > Research Themes > Cancer Science Institute of Singapore

  Cancer Science Institute of Singapore

 $172mil Research Centre of Excellence Grant over 7 years, by National Research Foundation and Ministry of Education

Director: Prof Daniel G. Tenen

Email: csidgt@nus.edu.sg


Deputy Director (Basic Programmes):
A/Prof Chng Wee Jooo
Email: csicwj@nus.edu.sg


Deputy Director (Translational and Clinical Programmes):
A/Prof Goh Boon Cher
Email: boon_cher_goh@nuhs.edu.sg


Cancer Science Institute of Singapore


Contact Details:

Ms Selena Gan

Administrative Director

CSI Singapore
National University of Singapore
14 Medical Drive, #12-01
Centre for Translational Medicine
Singapore 117599

Website: http://www.csi.nus.edu.sg/

  :    6516 1873
  :    6873 9664
  :    csigans@nus.edu.sg


The Cancer Science Institute of Singapore (CSI Singapore) is a state-of-the-art cancer research institute located within the National University of Singapore, and houses a full spectrum of cancer research and clinical translational facilities. Funded by the National Research Foundation (NRF) and Ministry of Education (MOE), CSI Singapore is led by a team of world-class scientists actively collaborating with renowned local and international institutes. 


With the vision to be recognised internationally as the premier centre for cutting-edge cancer research, CSI Singapore conducts a multi-faceted and coordinated approach to cancer research, extending from basic mechanistic studies leading all the way to experimental therapeutics. The institute houses a full spectrum of research and clinical translational facilities and focuses on cancers endemic to Asian populations such as gastric, liver and lung cancers.


Our research aims to develop novel approaches to understanding and treating prevalent cancers in Singapore and the region through two strong multidisciplinary programs:


  1. Cancer Stem Cells and Biology Programme
    Programme Leader: Prof. Daniel G. TENEN
  2. Experimental Therapeutics Programme
    Programme Leader: A/Prof. GOH Boon Cher


And Asian-centric types of cancers:


  1. Breast Cancer
    Group Leader: Prof. Peter LOBIE
    Breast cancer is the most common cancer in women worldwide. In Singapore, it accounts for 29.7% of female cancers and about 1,100 new cases are diagnosed with 270 deaths each year. This translates to about 3 women diagnosed every day and 1 death every other day.
  2. Gastric Cancer
    Group Leader: Prof. Yoshiaki ITO
    Almost 1 million deaths from gastric cancer occur every year, making it the 2nd leading cause of cancer deaths in the world. Asia-Pacific has the highest incidence of gastric cancer globally. It is the No. 5 killer cancer among men and No. 7 among women in Singapore.
  3. Leukaemia
    Group Leader: A/Prof. CHNG Wee Joo
    Leukaemias account for about 40% of all childhood cancers in Singapore and throughout the world. Although one of the most curable forms of cancers with a cure rate of 70% in childhood leukaemia, Singapore sees about 250 to 300 new patients every year.
  4. Liver Cancer
    Group Leader: Prof TEH Bin Tean
    Primary liver cancer or Hepatocellular Carcinoma (HCC) is the 4th most common cancer worldwide and 3rd most common cancer in Asia. 80% of the 1 million deaths from liver cancer occur in the Asia-Pacific. Singapore alone sees about 400 liver cancer deaths a year.
  5. Lung Cancer
    Group Leader: Dr. Ross SOO
    Lung cancer is the most frequently occurring cancer worldwide. It is the No. 1 killer cancer for both men and women in Asia-Pacific and Singapore.


Attracting World Class Talent

CSI Singapore counts some of the top cancer researchers worldwide as our principal investigators. We offer an unprecedented opportunity for a team of world-class scientists to develop fresh insights into the diagnosis and treatment of the disease.


PhD Graduate Programme

CSI Singapore aims to train the next generation of cancer researchers to excel in both the scientific and translational aspects of cancer research through its PhD Graduate Programme. This programme seeks high-calibre biomedical and medical graduates keen to pursue a career in cancer research.



Selected Publications

  1. Wu Y, Grabsch H, Ivanova T, Tan IB, Murray J, Ooi CH, Wright AI, West NP, Hutchins GG, Wu J, Lee M, Lee J, Koo JH, Yeoh KG, van Grieken N, Ylstra B, Rha SY, Ajani JA, Cheong JH, Noh SH, Lim KH, Boussioutas A, Lee JS, Tan P. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut. 2013 Aug; 62(8):1100-11.
  2. Do DV, Ueda J, Messerschmidt DM, Lorthongpanich C, Zhou Y, Feng B, Guo G, Lin PJ, Hossain MZ, Zhang W, Moh A, Wu Q, Robson P, Ng HH, Poellinger L, Knowles BB, Solter D,Fu XY.A genetic and developmental pathway from STAT3 to the OCT4-NANOG circuit is essential for maintenance of ICM lineages in vivo.Genes Dev. 2013 June; 27(12):1378-90.
  3. Yong KJ, Gao C, Lim JS, Yan B, Yang H, Dimitrov T, Kawasaki A, Ong CW, Wong KF, Lee S, Ravikumar S, Srivastava S, Tian X, Poon RT, Fan ST, Luk JM, Dan YY, Salto-Tellez M, Chai L,Tenen DG.Oncofetal gene SALL4 in aggressive hepatocellular carcinoma.N Engl J Med. 2013 June; 368(24):2266-76.
  4. Serra V,Eichhorn PJ, García-García C, Ibrahim YH, Prudkin L, Sánchez G, Rodríguez O, Antón P, Parra JL, Marlow S, Scaltriti M, Prat A, Arribas J, Hahn WC, Kim SY, Baselga J.RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.J Clin Invest. 2013 June; 123(6):2551-63.
  5. Yan J,Ng SB, Tay JL, Lin B, Koh TL, Tan J, Selvarajan V, Liu SC, Bi C, Wang S, Choo SN, Shimizu N, Huang G, Yu Q, Chng WJ.EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.Blood. 2013 May; 121(22):4512-20.
  6. Lin DC, Xu L, Ding LW, Sharma A, Liu LZ, Yang H, Tan P, Vadgama J, Karlan BY, Lester J, Urban N, Schummer M, Doan N, Said JW, Sun H, Walsh M, Thomas CJ, Patel P, Yin D, Chan D, Koeffler HP. Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. Proc Natl Acad Sci U S A. 2013 April; 110(15):6109-14.
  7. Bidard FC, Pierga JY, Soria JC,Thiery JP.Translating metastasis-related biomarkers to the clinic-progress and pitfalls. Nat Rev Clin Oncol. 2013 Mar; 10(3):169-79.
  8. Chen L, Li Y, Lin CH, Chan TH, Chow RK, Song Y, Liu M, Yuan YF, Fu L, Kong KL, Qi L, Li Y, Zhang N, Tong AH, Kwong DL, Man K, Lo CM, Lok S,Tenen DG, Guan XY.Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med. 2013 Feb; 19(2):209-16.
  9. Amabile G, Welner RS, Nombela-Arrieta C, D'Alise AM, Di Ruscio A, Ebralidze AK, Kraytsberg Y, Ye M, Kocher O, Neuberg DS, Khrapko K, Silberstein LE, Tenen DG. In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. Blood. 2013 Feb; 121(8):1255-64.
  10. Benoukraf T, Wongphayak S, Hadi LH, Wu M, Soong R. GBSA: a comprehensive software for analysing whole genome bisulfite sequencing data. Nucleic Acids Res. 2013 Feb; 41(4):e55.
  11. Das K, Lorena PD, Ng LK, Lim D, Shen L, Siow WY, Teh M, Reichardt JK, Salto-Tellez M. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. Endocr Relat Cancer. 2010 Aug 16; 17(3):757-70. 4.282
  12. Gueller S, Goodridge HS, Niebuhr B, Xing H, Koren-Michowitz M, Serve H, Underhill DM, Brandts CH, Koeffler HP. Adaptor protein Lnk inhibits c-Fms-mediated macrophage function. J Leukoc Biol. 2010 Jun 22. 4.403
  13. Iwanski GB, Lee DH, En-Gal S, Doan NB, Castor B, Vogt M, Toh M, Bokemeyer C, Said JW, Thoennissen NH, Koeffler HP. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br J Pharmacol. 2010 Jun; 160(4):998-1007. 5.204
  14. Lee CW, Ito K, Ito Y. Role of RUNX3 in bone morphogenetic protein signaling in colorectal cancer. Cancer Res. 2010 May 15; 70(10):4243-52. 7.543
  15. Kodama M, Otsubo C, Hirota T, Yokota J, Enari M, Taya Y. Requirement of ATM for rapid p53 phosphorylation at Ser46 without Ser/Thr-Gln sequences. Mol Cell Biol. 2010 Apr; 30(7):1620-33. 6.057
  16. Thoenissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T, Weiss T, Nowak D, Koren-Michowitz M, Kato M, Sanada M, Shih LY, Nagler A, Raynaud SD, Muller-Tidow C, Mesa R, Haferlach T, Gilliland DG, Tefferi A, Ogawa S, and Koeffler HP. Prevelence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2010 Apr 8; 115(14): 2882-90. 10.55
  17. Nowak D, Ogawa S, Müschen M, Kato M, Kawamata N, Meixel A, Nowak V, Kim HS, Kang S, Paquette R, Chang MS, Thoenissen NH, Mossner M, Hofmann WK, Kohlmann A, Weiss T, Haferlach T, Haferlach C, Koeffler HP. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood. 2010 Feb 4; 115(5):1049. 10.55
  18. Jacob B, Osato M, Yamashita N, Wang CQ, Taniuchi I, Littman DR, Asou N, Ito Y. Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis. Blood. 2010 Feb 25; 115(8):1610-20. 10.55
  19. Chang TL, Ito K, Ko TK, Liu Q, Yang S, Salto-Tellez M, Yeoh KG, Fukamachi H, Ito Y. Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology, 2010 Jan; 138(1):255-65. 12.899
  20. Guibal FC, Alberich-Jorda M, Hirai H, Ebralidze A, Levantini E, Di Ruscio A, Zhang P, Santana-Lemos BA, Neuberg D, Wagers AJ, Rego EM, Tenen DG. Identification of a myeloid committed progenitor as the cancer initiating cell in acute promyelocytic leukemia. Blood. 2009 Dec 24; 114(27):5415-25. 10.55